Oral Session 2-13C Hemophilia

[OS2-13C-5] Emicizumab in persons with hemophilia A (PwHA) without inhibitors: Results from HAVEN 3 study

Midori Shima¹, Johnny Mahlangu², Johannes Oldenburg³, Takashi Suzuki⁴, Yasuharu Nishida⁵, Tadashi Matsushita⁶, Toshihiro Ito⁷, Masashi Taki⁸, Katsuyuki Fukutake⁹, Ido Paz-Priel¹⁰, Claude Negrier¹¹, Markus Niggli¹², Maria Elisa Mancuso¹³, Christophe Schmitt¹², Victor Jime'Nez-Yuste¹⁴, Christine Kempton¹⁵, Christophe Dhalluin¹², Michael Callaghan¹⁶, Willem Bujan¹⁷, Joanne I. Adamkewicz¹⁰, Elina Asikanius¹², Sayaka Nagami¹⁸, Wataru Ohtsuka¹⁸, Koichiro Yoneyama¹⁸, Ryu Kasai¹⁸, Gallia G. Levy¹⁰, Rebecca Kruse-Jarres¹⁹ (1.Pediatrics, Nara Med Univ., Kashihara, Japan, 2.University of the Witwatersrand and NHLS, Johannesburg, South Africa, 3.Universitaetsklinikum Bonn, Bonn, Germany, 4.Department of Blood Coagulation, Ogikubo Hospital, Tokyo, Japan, 5.Division of Infectious Disease, NHO Osaka National Hospital, Osaka, Japan, 6.Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan, 7.Dep. of infect. dis., NHO Sendai National Hospital, Sendai, Japan, 8.Pediatrics, St. Marianna University School of Medicine, Kawasaki, Japan, 9.Labo-Med., Tokyo Med., Univ., Tokyo, Japan, 10.Genentech Inc, South San Francisco, California, USA, 11.Louis Pradel University Hospital, Lyon, France, 12.F. Hoffmann-La Roche Ltd, Basel, Switzerland, 13.Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy, 14.Hematology Department, Hospital Universitario La Paz, Auto'noma University, Madrid, Spain, 15.Emory School of Medicine, Atlanta, USA, 16.Children's Hospital of Michigan, Detroit, MI, USA, 17.Instituto Costarricense de Investigaciones Cienti'ficas, San Jose', Costa Rica, 18.Chugai Pharmaceutical co., ltd., Tokyo, Japan, 19.Washington Center for Bleeding Disorders, Seattle, WA, USA)